Table 2.

Univariate or multivariate cox proportional hazard ratios for overall survival time

	Hazard Ratio (95%CI)	P Value
Univariate Analysis
LRPPRC Intensity	2.64 (1.95–3.57)	<0.0001
LRPPRC Frequency	2.74 (2.07–3.63)	<0.0001
LRPPRC Levels	6.54 (3.41–12.56)	<0.0001
Metastasis	4.04 (2.57–6.34)	<0.0001
Clinical Stage	4.01 (2.55–6.32)	<0.0001
Gleason Score	3.14 (1.89–5.21)	<0.0001
Preoperative PSA	1.45 (1.10–1.91)	0.0083
HTSaf2*	0.18 (0.12–0.29)	<0.0001
HTSin2*	0.14 (0.07–0.30)	<0.0001
Multivariate Analysis
LRPPRC Levels	4.60 (2.26–9.37)	<0.0001
Gleason Score	2.99 (1.76–5.09)	<0.0001
Metastasis	2.09 (1.27–3.42)	0.0036
Clinical Stage	1.80 (1.06–3.07)	0.0311
Preoperative PSA	1.11 (0.82–1.49)	0.5031
HTSin2*	0.48 (0.22–1.03)	0.0598
HTSaf2*	0.46 (0.26–0.79)	0.0049

^*HTSin2: Hormone Therapy Sensitivity within 2 Years.

^*HTSaf2: Hormone Therapy Sensitivity after 2 Years.